Andrés Bratt-Leal, a co-founder of Aspen Neuroscience who is leading work there on a potential stem cell therapy for Parkinson’s disease, is among the recipients of the 2023 Life Science Catalyst Award given to young scientists and entrepreneurs in recognition of their contributions. Sponsored by…
The first patient has been dosed in a Phase 2 clinical trial testing AC Immune’s ACI-7104.056, an investigational vaccine targeting toxic alpha-synuclein forms to prevent nerve cell degeneration in Parkinson’s disease. AC Immune expects to complete the enrollment of the first group of patients in the VacSYn…
Buntanetap significantly reduced the levels of TDP-43 protein in the blood of people with Parkinson’s disease who participated in a Phase 2a clinical trial, according to clinical data from its developer Annovis Bio. The treatment also demonstrated a trend toward reducing other markers of inflammation. “We are pleasantly…
A five-year project funded by a $3.9 million National Institutes of Health (NIH) research grant will study how team-based palliative care might lead to better health services and ease disparities in Parkinson’s disease and disease-related dementia care. Palliative care focuses on improving the quality of life for individuals with…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a $10 million grant to Octave Biosciences to advance the development and validation of a protein biomarker panel assay for Parkinson’s disease. A biomarker assay for multiple proteins could offer a better tool to monitor and…
IntelGenx has won approval from the Swedish Medical Products Agency (MPA) to conduct a Phase 2 trial on Montelukast Versafilm, its proprietary oral thin film formulation, in people with Parkinson’s disease. The Phase 2 MONTPARK multicenter study will investigate the effectiveness of oral high-dose Montelukast on the progression…
Cerevance has dosed the first participant in a Phase 2 clinical trial evaluating the safety and efficacy of its investigational oral therapy CVN424 for Parkinson’s disease. The ASCEND trial (NCT06006247) will explore the safety and efficacy of CVN424 as a single therapy in people with early-stage…
A pilot trial into whether deep brain stimulation based on noninvasive neuromodulation of a lower leg nerve can safely and effectively ease symptoms of Parkinson’s disease and essential tremor is fully enrolled, Stimvia, its developer, announced. The 24 patients in the study (NCT06036368) will use the company’s…
UB-312, an experimental vaccine being developed for Parkinson’s disease by Vaxxinity, induced the production of antibodies targeting alpha-synuclein and slowed protein clumping in patients’ cerebrospinal fluid (CSF), the fluid that surrounds the brain and the spinal cord. The vaccine is designed to stimulate a patient’s immune system…
Biopas Laboratories has asked the regulatory agencies of six countries in Latin America to approve Inbrija for Parkinson’s disease off periods, according to Acorda Therapeutics, the therapy’s developer and Biopas’ partner. Inbrija is a self-administered, inhaled levodopa therapy developed to reduce periods when motor symptoms are…
Get regular updates to your inbox.
